Glass House Brands Inc.

GLAS
Country: United StatesPrice: $1.27Market Cap: $119.7M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

2 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2110 (Top 68.1%)FAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-24

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 4✗ 24▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / Book Value per Share1.4x
      ✗Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio1.4x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-9.8%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-9.8%, ROC=-6.9%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)9.1x
      ✗Dreman< 8x
      Valuation ReasonablenessOE Yield=-40.2%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-13.1%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=1.4x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low100% of trailing low ($1.27)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-24.78%; #4692/6340 (top 74.0%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.6177; #2469/6449 (top 38.3%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share1.67x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change-27.0%
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+1.5205; #1318/5247 (top 25.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-13.14%; #3336/4519 (top 73.8%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-88.55%; #5964/6202 (top 96.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Verdicts0% pass✗ 15▾

      Split decision: 14 FAIL · 2 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (0/7)✗GreenblattRank #2110✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (1/11)✗MungerFAIL (0/4)✗PabraiFAIL (1/3)✗AkreFAIL (0/6)✗MarksFAIL (1/5)✗AckmanFAIL (3/9)•TempletonNEUTRAL (5/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #2180/2370 (Top 92.0%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
    • Cash Flow10% pass✓ 2✗ 10▾

      9 of 10 flag GLAS's cash flow — Buffett, Lynch, Dreman +6 more

      Free Cash Flow Proxy$-41.8M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-15.7M
      ✗LynchPositive and growing
      Operating Cash Flow$11.4M
      ✓PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=3.59%, ROA=-9.31%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)9.1x
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-13.1%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive2/6 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-15.1%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency3/6 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-15.7M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-13.14%; #3336/4519 (top 73.8%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Profitability13% pass✓ 5✗ 30▾

      14 of 16 flag GLAS's profitability — Graham, Buffett, Lynch +11 more

      Positive EPS (10 years)0/7 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)1/7 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-38.5%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-9.1% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-41.8M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-40.1%
      ✗Lynch> 15%
      EBIT / Enterprise Value-9.8%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-9.8%, ROC=-6.9%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-9.31%
      ✗PiotroskiROA > 0
      ROA Change YoY0.17% -> -9.31% (delta: -9.48%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=3.59%, ROA=-9.31%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY48.5% -> 42.3%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-9.4%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-40.1%
      ✗Dreman> 12%
      Margin of SafetyP/B=1.4x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-49.7% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency1/6 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-9.1%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-40.1%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-30.8% (2023) -> -9.1% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 50.3% -> 42.3%, operating margin -30.8% -> -9.1%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-24.78%; #4692/6340 (top 74.0%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+24.16%; #1782/3702 (top 48.1%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-40.11%; #4085/5226 (top 78.2%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.1075; #3567/5884 (top 60.6%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/6 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Growth13% pass✓ 3✗ 10▾

      7 of 8 flag GLAS's growth — Graham, Lynch, Dreman +4 more

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: 84.0% vs Rev: -9.4%
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency1/6 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth24.9%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 50.3% -> 42.3%, operating margin -30.8% -> -9.1%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR30.4%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency13% pass✓ 2✗ 9▾

      7 of 8 flag GLAS's efficiency — Graham, Buffett, Greenblatt +4 more

      Current Ratio1.78
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-15.1%
      ✗Buffett> 10%
      ROIC - WACC-25.1%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-6.9%
      ✗Greenblatt> 25%
      Current Ratio Change YoY0.99 -> 1.78
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.65x -> 0.57x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities1.78
      ✓Dreman> 1.5
      Return on Invested Capital-9.2%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-25.4%; FY2024: ROIC=2.6%; FY2025: ROIC=-9.2%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest -9.2%)
      ✗SleepROIC > 12% in a majority of years
    • Debt & Leverage25% pass✓ 5✗ 10▾

      9 of 12 flag GLAS's debt & leverage — Graham, Buffett, Lynch +6 more

      Total Debt / Shareholders' Equity0.93
      ✗Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      LT Debt vs Net Current AssetsLT Debt $68.6M vs NCA $29.8M
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.93, IC: -3.7x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0.93
      ✗Lynch< 0.33
      Cash - Long-term Debt$-48.8M
      ✗LynchPositive preferred
      LT Debt / Total Assets Change16.28% -> 21.54%
      ✗PiotroskiDecreased YoY
      Current Assets / Current Liabilities1.78
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Debt Levels0.93
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-3.7x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0.93
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.9287; #3141/4210 (top 74.6%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($119.7M)
    Revenue: $182.0M-9.4% YoY
    Net Income: $29.7M-5814.6% YoY

    Financial Snapshot

    Operating Margin-9.1%
    Return on Equity-40.1%
    Debt / Equity0.93
    Current Ratio1.78
    EPS (Diluted)$-0.55
    Shares Retired−8.9% / −13.8% 2y

    Shareholder Return

    Fiscal 2025

    Issued 8.9% of shares last year, 13.8% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    MetricFY 2025
    Sources
    • 40-F · 2026-03-24
    FY 2024
    Sources
    • 40-F · 2025-03-25
    FY 2023
    Sources
    • 40-F · 2024-04-01
    FY 2022
    Sources
    • 40-F · 2023-03-31
    FY 2021
    Sources
    • 40-F/A · 2022-04-01
    Market Cap$119.7Mcurrent$421.3Mest.$446.6Mest.$166.9Mest.$195.8Mest.
    Revenue$182.0M↓9%$200.9M↑25%$160.8M↑89%$84.9M↑34%$63.2M
    Operating Income-$16.5M↓388%$5.7M↑112%-$49.5M↑12%-$56.4M↓56%-$36.2M
    Net Income-$29.7M↓5815%$519.0K↑101%-$98.3M↓199%-$32.9M↑24%-$43.1M
    EPS (Diluted)$-0.55↓162%$-0.21↑87%$-1.62↓86%$-0.87↑23%$-1.13
    Gross Margin42.3%↓13%48.5%↓4%50.3%↑106%24.4%↓2%25.0%
    Operating Margin-9.1%↓418%2.9%↑109%-30.8%↑54%-66.4%↓16%-57.2%
    ROE-40.1%↓9084%0.4%↑100%-109.5%↓462%-19.5%↑18%-23.7%
    Total Debt$68.7M↑18%$58.2M↓9%$64.1M↑2%$62.7M↑40%$44.9M
    Shareholders' Equity$73.9M↓36%$116.2M↑29%$89.8M↓47%$168.9M↓7%$182.1M
    Current Ratio1.78↑80%0.99↑76%0.56↓22%0.72↓42%1.24
    Debt / Equity0.93↑85%0.50↓30%0.71↑92%0.37↑51%0.25
    Operating Cash Flow$11.4M↓60%$28.4M↑22%$23.2M↑157%-$40.8M↓101%-$20.3M
    Free Cash Flow-$15.7M↓187%$18.1M↑66%$10.9M↑116%-$68.6M↑47%-$128.8M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    GLAS vs Peers — Financial Grading

    Revenue$182.0MBottom 25%
    Net Income$29.7MBottom 25%
    ROE-40.1%Bottom 25%
    D/E0.93Median
    Op. Margin-9.1%Bottom 25%
    Curr. Ratio1.78Median
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11